|
40 Companies |
|
48 Products |
|
48 Products |
|
0 Mechanisms of Action |
|
20 Trials |
|
419 News |
|
| «12345678 |
- enalapril / Generic mfg.
Enrollment change: MADREPIEC: Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children (clinicaltrials.gov) - Jul 24, 2012
P=N/A, N=5, Terminated, Sponsor: Assistance Publique - H
N=400 --> 5
- Integrilin (eptifibatide) / Takeda
Enrollment change: A Safety Study of Eptifibatide in Patients With Sickle Cell Disease (clinicaltrials.gov) - Jul 9, 2012
P1/2, N=13, Terminated, Sponsor: University of North Carolina, Chapel Hill
N=400 --> 5 N=30 --> 13
- sodium nitrite / Hope Pharm
Trial termination: Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease (clinicaltrials.gov) - Jun 10, 2012
P1/2, N=5, Terminated, Sponsor: Children's Hospital Los Angeles
N=30 --> 13 Recruiting --> Terminated; Low enrollment
- sodium nitrite / Hope Pharm
Enrollment change: Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease (clinicaltrials.gov) - Jun 10, 2012
P1/2, N=5, Terminated, Sponsor: Children's Hospital Los Angeles
Recruiting --> Terminated; Low enrollment N=30 --> 5
- hydroxyurea / Generic mfg.
New P4 trial: HYDREP: Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated (clinicaltrials.gov) - May 29, 2012
P4, N=50, Completed, Sponsor: Assistance Publique - H
- Clinical: Improving Emergency Department Management of Adults With Sickle Cell Disease (clinicaltrials.gov) - May 20, 2012
P=N/A, N=500, Enrolling by invitation, Sponsor: Duke University
- | HQK 1001 / Viracta Therap
New P2 trial: Effects of HQK-1001 in Patients With Sickle Cell Disease (clinicaltrials.gov) - May 16, 2012
P2, N=77, Terminated, Sponsor: HemaQuest Pharmaceuticals Inc.
- Enrollment open: The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease (clinicaltrials.gov) - May 16, 2012
P=N/A, N=110, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=30 --> 5 Not yet recruiting --> Recruiting
- morphine sulphate / Generic mfg., dextromethorphan / Generic mfg.
Enrollment change: Assessment of Opioid Analgesia in Sickle Cell (clinicaltrials.gov) - Apr 30, 2012
P4, N=62, Completed, Sponsor: Children's Research Institute
Not yet recruiting --> Recruiting N=200 --> 62
- morphine sulphate / Generic mfg., dextromethorphan / Generic mfg.
Trial completion: Assessment of Opioid Analgesia in Sickle Cell (clinicaltrials.gov) - Apr 30, 2012
P4, N=62, Completed, Sponsor: Children's Research Institute
N=200 --> 62 Recruiting --> Completed
- Clinical: Bi-Level Positive Airway Ventilation for Acute Chest Syndrome (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=60, Not yet recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- |||| HQK 1001 / Viracta Therap
Trial completion: A Study of HQK-1001 in Patients With Sickle Cell Disease (clinicaltrials.gov) - Apr 10, 2012
P2, N=52, Completed, Sponsor: HemaQuest Pharmaceuticals Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- Amevive (alefacept) / Astellas
Trial suspension: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=5, Suspended, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Suspended
- Clinical: Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program (clinicaltrials.gov) - Apr 1, 2012
P=N/A, N=72, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Clinical: Blood Flow and Pain Crises in People With Sickle Cell Disease (clinicaltrials.gov) - Mar 29, 2012
P=N/A, N=120, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- imatinib / Generic mfg., carvedilol / Generic mfg.
New P1 trial: Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease (clinicaltrials.gov) - Mar 29, 2012
P1, N=0, Withdrawn, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- || New P2/3 trial: SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) - Mar 27, 2012
P2/3, N=280, Recruiting, Sponsor: Assistance Publique - H
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
New P2 trial: Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease (clinicaltrials.gov) - Mar 26, 2012
P2, N=15, Recruiting, Sponsor: University of Pittsburgh
- Trial initiation date: Safety Study of MP4CO in Adult Sickle Cell Patients (clinicaltrials.gov) - Mar 22, 2012
P1, N=32, Completed, Sponsor: Sangart
Recruiting --> Suspended Initiation date: Oct 2011 --> Jan 2012
- varespladib (A-002) / Anthera Pharma, Ophirex
Trial termination: IMPACTS-2: A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (clinicaltrials.gov) - Mar 20, 2012
P2, N=2, Terminated, Sponsor: Anthera Pharmaceuticals
Initiation date: Oct 2011 --> Jan 2012 Not yet recruiting --> Terminated; change in company plans
- varespladib (A-002) / Anthera Pharma, Ophirex
Enrollment change: IMPACTS-2: A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (clinicaltrials.gov) - Mar 20, 2012
P2, N=2, Terminated, Sponsor: Anthera Pharmaceuticals
Not yet recruiting --> Terminated; change in company plans N=150 --> 2
- hydroxyurea / Generic mfg.
Trial initiation date: Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) (clinicaltrials.gov) - Mar 6, 2012
P3, N=38, Terminated, Sponsor: Children's Hospital Medical Center, Cincinnati
N=150 --> 2 Initiation date: Feb 2012 --> May 2012
- ||||||| vepoloxamer (MST-188) / Savara
Trial completion: Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease (clinicaltrials.gov) - Mar 4, 2012
P3, N=300, Completed, Sponsor: Mast Therapeutics, Inc.
Initiation date: Feb 2012 --> May 2012 Terminated --> Completed
- hydroxyurea / Generic mfg.
New P3 trial: Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) (clinicaltrials.gov) - Feb 9, 2012
P3, N=38, Terminated, Sponsor: Children's Hospital Medical Center, Cincinnati
- simvastatin / Generic mfg.
Trial completion: Simvastatin (Zocor) Therapy in Sickle Cell Disease (clinicaltrials.gov) - Feb 8, 2012
P1/2, N=42, Completed, Sponsor: Children's Hospital & Research Center Oakland
Terminated --> Completed Recruiting --> Completed
- Ibsrela (tenapanor) / Ardelyx, Kyowa Kirin, Knight Therap, deferitazole (SHP602) / Takeda
Enrollment change: Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload (clinicaltrials.gov) - Feb 7, 2012
P1b, N=20, Completed, Sponsor: FerroKin BioSciences, Inc.
Recruiting --> Completed N=16 --> 20
- varespladib (A-002) / Anthera Pharma, Ophirex
New P2 trial: IMPACTS-2: A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (clinicaltrials.gov) - Jan 29, 2012
P2, N=2, Terminated, Sponsor: Anthera Pharmaceuticals
- New P2 trial: Effectiveness of Laying-on-of-hands for Sickle Cell Disease (clinicaltrials.gov) - Jan 20, 2012
P2, N=40, Completed, Sponsor: MOA Health Science Foundation
- | varespladib (A-002) / Anthera Pharma, Ophirex
Enrollment change: IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (clinicaltrials.gov) - Jan 17, 2012
P2, N=30, Completed, Sponsor: Anthera Pharmaceuticals
N=16 --> 20 N=60 --> 30
- hydroxyurea / Generic mfg.
New P1 trial: Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia (clinicaltrials.gov) - Jan 8, 2012
P1, N=40, Recruiting, Sponsor: Children's Mercy Hospital Kansas City
- | prasugrel / Generic mfg.
New P2 trial: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (clinicaltrials.gov) - Nov 20, 2011
P2, N=33, Completed, Sponsor: Eli Lilly and Company
- zoledronic acid / Generic mfg.
Trial withdrawal: Phase 1 Study of Zoledronic Acid in Sickle Cell Disease (clinicaltrials.gov) - Nov 9, 2011
P1/2, N=0, Withdrawn, Sponsor: Virginia Commonwealth University
N=60 --> 30 Terminated --> Withdrawn
- Enrollment change, IO biomarker: A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension (clinicaltrials.gov) - Nov 3, 2011
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Terminated --> Withdrawn N=20 --> 0
- | prasugrel / Generic mfg.
Trial completion: A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet (clinicaltrials.gov) - Oct 13, 2011
P1, N=18, Completed, Sponsor: Eli Lilly and Company
N=20 --> 0 Active, not recruiting --> Completed
- | prasugrel / Generic mfg.
New P1 trial: A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet (clinicaltrials.gov) - Sep 5, 2011
P1, N=18, Completed, Sponsor: Eli Lilly and Company
- Trial completion, Adverse events: Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=100, Completed, Sponsor: HaEmek Medical Center, Israel
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=50, Completed, Sponsor: HaEmek Medical Center, Israel
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=60, Completed, Sponsor: HaEmek Medical Center, Israel
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=50, Completed, Sponsor: HaEmek Medical Center, Israel
Recruiting --> Completed Not yet recruiting --> Completed
- Trial completion: Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=50, Completed, Sponsor: HaEmek Medical Center, Israel
Not yet recruiting --> Completed Recruiting --> Completed
- | Fragmin (dalteparin sodium) / Pfizer, Eisai
New P2 trial: Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo (clinicaltrials.gov) - Aug 17, 2011
P2, N=34, Active, not recruiting, Sponsor: Duke University